Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.
Boers J, Eisses B, Zwager MC, van Geel JJL, Bensch F, de Vries EFJ, Hospers GAP, Glaudemans AWJM, Brouwers AH, den Dekker MAM, Elias SG, Kuip EJM, van Herpen CML, Jager A, van der Veldt AAM, Oprea-Lager DE, de Vries EGE, van der Vegt B, Menke-van der Houven van Oordt WC, Schröder CP; IMPACT-Metastatic Breast Consortium. Boers J, et al. Among authors: van herpen cml. Diagnostics (Basel). 2024 Feb 14;14(4):416. doi: 10.3390/diagnostics14040416. Diagnostics (Basel). 2024. PMID: 38396455 Free PMC article.
Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.
Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, Oosting SF, Aarntzen EH, Brouwers AH, Kwee TC, Heskamp S, Hoekstra OS, Verheul H, van der Veldt AAM, de Vries EGE, Boerman OC, van der Graaf WTA, Oyen WJG, van Herpen CML. Verhoeff SR, et al. Among authors: van helden e, van der veldt aam, van der graaf wta, van herpen cml, van es sc. Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1931-1939. doi: 10.1007/s00259-019-04358-9. Epub 2019 Jun 6. Eur J Nucl Med Mol Imaging. 2019. PMID: 31172212 Free PMC article. Clinical Trial.
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P. Banerji U, et al. Among authors: van herpen cml. Lancet Oncol. 2019 Aug;20(8):1124-1135. doi: 10.1016/S1470-2045(19)30328-6. Epub 2019 Jun 27. Lancet Oncol. 2019. PMID: 31257177 Free article. Clinical Trial.
Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.
van Es SC, van der Vegt B, Bensch F, Gerritse S, van Helden EJ, Boon E, Angus L, Overbosch J, Menke-van der Houven van Oordt CW, Verheul HM, van Herpen CML, Jager A, Oosting SF, de Vries EGE, Schröder CP. van Es SC, et al. Among authors: van helden ej, van herpen cml, van der vegt b. Am J Surg Pathol. 2019 Oct;43(10):1355-1360. doi: 10.1097/PAS.0000000000001321. Am J Surg Pathol. 2019. PMID: 31283631
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden EJ, Angus L, Menke-van der Houven van Oordt CW, Heideman DAM, Boon E, van Es SC, Radema SA, van Herpen CML, de Groot DJA, de Vries EGE, Jansen MPHM, Sleijfer S, Verheul HMW. van Helden EJ, et al. Among authors: van herpen cml, van es sc. Mol Oncol. 2019 Nov;13(11):2361-2374. doi: 10.1002/1878-0261.12550. Epub 2019 Sep 30. Mol Oncol. 2019. PMID: 31350822 Free PMC article.
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.
van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC, van Grieken NCT, Dekker H, van Dongen GAMS, Vugts DJ, Boellaard R, van Herpen CML, de Vries EGE, Oyen WJG, Brouwers AH, Verheul HMW, Hoekstra OS, Menke-van der Houven van Oordt CW. van Helden EJ, et al. Among authors: van herpen cml, van es sc, van dongen gams, van grieken nct. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):849-859. doi: 10.1007/s00259-019-04555-6. Epub 2019 Nov 9. Eur J Nucl Med Mol Imaging. 2020. PMID: 31705176 Free PMC article.
Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.
van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC, van Grieken NCT, Dekker H, van Dongen GAMS, Vugts DJ, Boellaard R, van Herpen CML, de Vries EGE, Oyen WJG, Brouwers AH, Verheul HMW, Hoekstra OS, der Houven van Oordt CWM. van Helden EJ, et al. Among authors: van herpen cml, van es sc, van dongen gams, van grieken nct. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2481. doi: 10.1007/s00259-020-04908-6. Eur J Nucl Med Mol Imaging. 2020. PMID: 32535653 Free PMC article.
89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer.
Verhoeff SR, van de Donk PP, Aarntzen EHJG, Oosting SF, Brouwers AH, Miedema IHC, Voortman J, Menke-van der Houven van Oordt WC, Boellaard R, Vriens D, Slingerland M, Hermsen R, Grunsven IVE, Heskamp S, van Herpen CML. Verhoeff SR, et al. Among authors: van herpen cml, van de donk pp. J Nucl Med. 2022 Oct;63(10):1523-1530. doi: 10.2967/jnumed.121.263470. Epub 2022 May 5. J Nucl Med. 2022. PMID: 35512998 Free PMC article.
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma.
Verhoeff SR, Oosting SF, Elias SG, van Es SC, Gerritse SL, Angus L, Heskamp S, Desar IME, Menke-van der Houven van Oordt CW, van der Veldt AAM, Arens AIJ, Brouwers AH, Eisses B, Mulders PFA, Hoekstra OS, Zwezerijnen GJC, van der Graaf WTA, Aarntzen EHJG, Oyen WJG, van Herpen CML. Verhoeff SR, et al. Among authors: van der veldt aam, van der graaf wta, van herpen cml, van es sc. Clin Cancer Res. 2023 Feb 1;29(3):592-601. doi: 10.1158/1078-0432.CCR-22-0921. Clin Cancer Res. 2023. PMID: 36394882 Free PMC article.
229 results